<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02057133</url>
  </required_header>
  <id_info>
    <org_study_id>15252</org_study_id>
    <secondary_id>I3Y-MC-JPBH</secondary_id>
    <nct_id>NCT02057133</nct_id>
  </id_info>
  <brief_title>A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread</brief_title>
  <official_title>A Phase 1b Study of Abemaciclib in Combination With Therapies for Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety of abemaciclib in combination therapies (letrozole,
      anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus
      fulvestrant, pertuzumab plus trastuzumab with loperamide) for breast cancer that has spread
      to other parts of the body.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 10, 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Drug-Related Adverse Events</measure>
    <time_frame>Baseline through study completion (estimated as 12 months)</time_frame>
    <description>Number of participants with one or more drug-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, and Fulvestrant, and Pertuzumab</measure>
    <time_frame>Cycle 1 up to Cycle 5 (21 or 28 Day Cycle): Predose and at multiple timepoints, depending on study part.</time_frame>
    <description>Cmax of LY2835219, letrozole, anastrozole, tamoxifen, exemestane, everolimus, trastuzumab, LY3023414, and fulvestrant, and pertuzumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with a Complete or Partial Tumor Response (Overall Response Rate)</measure>
    <time_frame>Baseline to study completion (estimated as 12 months)</time_frame>
    <description>Number of participants with a complete or partial tumor response (overall response rate).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>First dose to progressive disease or death of any cause (estimated as 12 months)</time_frame>
    <description>Progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MD Anderson Symptom Inventory (MDASI) Score from Baseline</measure>
    <time_frame>Baseline, through study completion (estimated as 12 months)</time_frame>
    <description>Change in MD Anderson (MDASI) score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the Curve (AUC) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, Everolimus, Trastuzumab, LY3023414, and Fulvestrant, and Pertuzumab</measure>
    <time_frame>Cycle 1 up to Cycle 5 (21 or 28 Day Cycle): Predose and at multiple timepoints, depending on study part.</time_frame>
    <description>Pharmacokinetics: AUC of LY2835219, letrozole, anastrozole, tamoxifen, exemestane, everolimus, trastuzumab, LY3023414, and fulvestrant, and pertuzumab.</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>LY2835219 + Letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Letrozole administered orally. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Anastrozole administered orally. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Tamoxifen administered orally. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Exemestane administered orally. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Exemestane administered orally. Everolimus administered orally. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219+ Trastuzumab Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Trastuzumab administered intravenously (IV) infusion. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219+ Trastuzumab Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Trastuzumab administered IV infusion. This arm is closed to enrollment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered intramuscularly (IM).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3023414 administered orally. LY2835219 administered orally. Fulvestrant administered IM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hormone Receptor Negative (HR-): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion.
Hormone Receptor Positive (HR+): LY2835219 administered orally. Loperamide administered orally. Trastuzumab administered IV infusion. Pertuzumab administered IV infusion. Endocrine therapy administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2835219 + Endocrine Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2835219 administered orally. Ongoing endocrine therapy administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2835219</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Letrozole</arm_group_label>
    <arm_group_label>LY2835219 + Anastrozole</arm_group_label>
    <arm_group_label>LY2835219 + Tamoxifen</arm_group_label>
    <arm_group_label>LY2835219 + Exemestane</arm_group_label>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Expansion</arm_group_label>
    <arm_group_label>LY2835219+ Trastuzumab Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219+ Trastuzumab Dose Expansion</arm_group_label>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Escalation</arm_group_label>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Expansion</arm_group_label>
    <arm_group_label>LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion</arm_group_label>
    <arm_group_label>LY2835219 + Endocrine Therapy</arm_group_label>
    <other_name>Abemaciclib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Anastrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Tamoxifen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Exemestane</arm_group_label>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219 + Exemestane + Everolimus Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Administered IV infusion.</description>
    <arm_group_label>LY2835219+ Trastuzumab Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219+ Trastuzumab Dose Expansion</arm_group_label>
    <arm_group_label>LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3023414</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Escalation</arm_group_label>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Administered IM.</description>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Escalation</arm_group_label>
    <arm_group_label>LY3023414 + LY2835219 + Fulvestrant Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>Administered IV infusion.</description>
    <arm_group_label>LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loperamide</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>LY2835219 +Trastuzumab +Pertuzumab +Loperamide Dose Escalation</arm_group_label>
    <arm_group_label>LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Endocrine therapy</intervention_name>
    <description>Endocrine therapy administered orally.</description>
    <arm_group_label>LY2835219 +Trastuzumab + Pertuzumab +Loperamide Dose Expansion</arm_group_label>
    <arm_group_label>LY2835219 + Endocrine Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor
             receptor 2 (HER2) negative metastatic breast cancer for Parts A to E, G, and I.

          -  Have a diagnosis of human epidermal growth factor receptor 2 (HER2) positive
             metastatic breast cancer for Parts F and H.

          -  For Part A (LY2835219 + letrozole): Except for ongoing therapy with letrozole, the
             participant must not have received prior systemic endocrine therapy for metastatic
             disease.

          -  For Part B (LY2835219 + anastrozole): Except for ongoing therapy with anastrozole, the
             participant must not have received prior systemic endocrine therapy for metastatic
             disease.

          -  For Part C (LY2835219 + tamoxifen): The participant may have received prior systemic
             endocrine therapy for metastatic disease and may be receiving ongoing therapy with
             tamoxifen.

          -  For Part D (LY2835219 + exemestane): The participant must have received prior systemic
             endocrine therapy with at least one nonsteroidal aromatase inhibitor (anastrozole,
             letrozole) for metastatic disease and may be receiving ongoing therapy with
             exemestane.

          -  For Part E (LY2835219 + exemestane + everolimus): The participant must have received
             prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor
             (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy
             with either exemestane or exemestane + everolimus.

          -  For Part F (LY2835219 + trastuzumab):The participant must have received at least 1
             chemotherapy regimen for metastatic disease and may be receiving ongoing therapy with
             trastuzumab. The participant must have an estimated left ventricular ejection fraction
             within the normal range by either echocardiogram or multigated acquisition (MUGA) scan

          -  For Part G (abemaciclib + LY3023414 + fulvestrant): The participant may have received
             prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor
             (anastrozole, letrozole) for metastatic disease.

          -  For Part H: (abemaciclib + trastuzumab + pertuzumab): The participant must have
             received at least 1 chemotherapy regimen for metastatic disease. The participant may
             be receiving ongoing therapy with trastuzumab and/or pertuzumab at the time of study
             entry. The participant must have an estimated left ventricular ejection fraction
             (LVEF) within the normal range by either echocardiogram or multigated acquisition
             (MUGA) scan.

          -  For Part I (abemaciclib + endocrine therapy): The participant must have demonstrated
             evidence of disease progression on a Cyclin Dependent Kinase 4 (CDK4) and Cyclin
             Dependent Kinase 6 (CDK6) inhibitor (either palbociclib or ribociclib) plus endocrine
             therapy for advanced or metastatic disease as the most recent therapy immediately
             preceding study entry. The participant should remain on the current endocrine therapy
             while receiving abemaciclib.

          -  For Parts A, B, C, D, E, and F: Have either measureable disease or nonmeasureable but
             evaluable bone disease as defined by the Response Evaluation Criteria in Solid Tumors
             (RECIST 1.1)

          -  For Part G, H, and I: Have measureable disease as defined by RECIST 1.1.

          -  For all Parts except Part F and H: Participants must have either post-menopausal
             status or pre-menopausal status if continuing or beginning ovarian suppression with a
             luteinizing hormone-releasing hormone (LHRH) agonist such as goserelin.

          -  Parts H, and I: Must be able and willing to undergo mandatory tumor biopsies prior to
             study treatment and at the time of discontinuation from study treatment.

          -  Have adequate organ function, including:

               -  Hematologic: Absolute neutrophil count (ANC) ≥1.5 x 10^9/liter (L), platelets ≥
                  100 x 10^9/L, and hemoglobin ≥ 8 gram/deciliter (g/dL).

               -  Hepatic: Bilirubin ≤1.5 times upper limits of normal (ULN), alanine
                  aminotransferase (ALT) ≤ 3.0 times ULN.

               -  Renal: Serum creatinine ≤ 1.5 times ULN.

          -  Have a performance status of ≤1 on the Eastern Cooperative Oncology Group (ECOG)
             scale.

          -  Have discontinued all previous therapies for breast cancer (including chemotherapy,
             radiotherapy, immunotherapy, and investigational therapy), except for ongoing
             corresponding combination therapy, for at least 21 days for myelosuppressive agents or
             14 days for nonmyelosuppressive agents prior to receiving study drug(s), and recovered
             from the acute effects of therapy (until the toxicity resolves to either baseline or
             at least Grade 1) except for residual alopecia or peripheral neuropathy. For Part F
             and H: concurrent treatment with trastuzumab emtansine (T-DM1) is not allowed.

        Exclusion Criteria:

          -  Have metastatic breast cancer with severe organ dysfunction as assessed by symptoms
             and signs, laboratory studies, and rapid progression of the disease.

          -  Have brain metastasis without prior radiotherapy.

          -  For Parts A, B, C, D, E, G and I: Have received prior systemic chemotherapy for
             metastatic disease. However, the participant may have received prior systemic
             chemotherapy in the neoadjuvant or adjuvant setting.

          -  For Parts A, B, C, D, E, F, H: Have received prior therapy with a CDK4/6 inhibitor,
             Part G: Have received prior therapy with fulvestrant or any PI3K and/or mTOR inhibitor
             (including LY3023414); Part I: Have received prior treatment with abemaciclib in any
             setting.

          -  Have serious preexisting medical conditions that, in the judgment of the investigator,
             would preclude participation in this study (for example, history of major surgical
             resection involving the stomach or small bowel).

          -  Have central nervous system (CNS) metastasis with either radiotherapy or development
             of neurological changes ≤14 days prior to receiving study treatment. Participants may
             be receiving a stable dose of corticosteroids. Screening of asymptomatic participants
             without history of CNS metastasis is not required. Untreated CNS metastases are not
             permitted.

          -  For Parts F and H: Cardiac disease including myocardial infarction within 6 months,
             unstable angina, or New York Heart Association (NYHA) Grade II or greater functional
             impairment.

          -  For Part G: Have type 1 diabetes mellitus or a history of gestational diabetes
             mellitus. Participants with a type 2 diabetes mellitus are eligible if adequate
             control of blood glucose level is obtained with oral therapy as documented by
             Hemoglobin A1c &lt;7%.

          -  For Part G: Have a baseline electrocardiogram (obtained from Day -14 to Day -1) with
             any of the following abnormal findings: ventricular arrhythmia, evidence of acute
             myocardial ischemia, heart block (of any degree), or QTc prolongation (defined as QTcB
             ≥450 milliseconds).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>479-587-1700</phone>
    </contact>
    <investigator>
      <last_name>Joseph Beck</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-822-6135</phone>
    </contact>
    <investigator>
      <last_name>Teresa Helsten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-5869</phone>
    </contact>
    <investigator>
      <last_name>Sara Tolaney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-266-6264</phone>
    </contact>
    <investigator>
      <last_name>Matthew Goetz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Phys &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-305-1945</phone>
    </contact>
    <investigator>
      <last_name>Kevin Kalinsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-888-4560</phone>
    </contact>
    <investigator>
      <last_name>Maura Dickler</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-843-7714</phone>
    </contact>
    <investigator>
      <last_name>E. Claire Dees</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>405-271-4022</phone>
    </contact>
    <investigator>
      <last_name>Kathleen Moore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center Oncology Hematology Care</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>506-216-8636</phone>
    </contact>
    <investigator>
      <last_name>Alison Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh Cancer Inst. (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>412-641-3494</phone>
    </contact>
    <investigator>
      <last_name>Shannon Puhalla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Howard Burris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-936-3524</phone>
    </contact>
    <investigator>
      <last_name>Brent Rexer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229-3307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>210-593-5250</phone>
    </contact>
    <investigator>
      <last_name>Muralidhar Beeram</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SMO US Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/breast-cancer/JPBH#?postal=</url>
    <description>Click here for more information about this study: A Study of Abemaciclib (LY2835219) in Combination With Other Therapies in Participants With Breast Cancer That Has Spread</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2014</study_first_submitted>
  <study_first_submitted_qc>February 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2014</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

